Cargando…
How do I see the production of engineered blood cells available for transfusion?
The in vitro production of red blood cells and platelets is a groundbreaking technology that can—when optimized—surrogate for donated blood cells, in total or in part. Here we discuss questions that may arise when the technology is available, relative to safety issues (comprising both quantitative a...
Autor principal: | Garraud, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323659/ https://www.ncbi.nlm.nih.gov/pubmed/32631500 http://dx.doi.org/10.1016/j.transci.2020.102863 |
Ejemplares similares
-
How do I/We forecast tomorrow’s transfusion? A series of experts’ proposals for changes in transfusion medicine
por: Garraud, Olivier, et al.
Publicado: (2022) -
How do I/we forecast tomorrows’ transfusion: Blood components
por: Pereyra, Nicolas, et al.
Publicado: (2023) -
How Can Eastern/Southern Mediterranean Countries Resolve Quality and Safety Issues in Transfusion Medicine?
por: Haddad, Antoine, et al.
Publicado: (2018) -
Immunological Features in the Process of Blood Platelet-Induced Alloimmunisation, with a Focus on Platelet Component Transfusion
por: Garraud, Olivier, et al.
Publicado: (2019) -
Non-leukodepleted red blood cell transfusion in sepsis patients: beyond oxygenation, is there a risk of inflammation?
por: Garraud, Olivier, et al.
Publicado: (2014)